1. Home
  2. IMNM vs ELMD Comparison

IMNM vs ELMD Comparison

Compare IMNM & ELMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$21.49

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Electromed Inc.

ELMD

Electromed Inc.

HOLD

Current Price

$27.81

Market Cap

326.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
ELMD
Founded
2006
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
326.9M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
IMNM
ELMD
Price
$21.49
$27.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
3
Target Price
$32.80
★ $36.00
AVG Volume (30 Days)
★ 975.9K
98.7K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
★ 52.94
EPS
N/A
★ 1.30
Revenue
$6,941,000.00
★ $54,716,000.00
Revenue This Year
N/A
$15.59
Revenue Next Year
$1,127.34
$11.51
P/E Ratio
★ N/A
$21.43
Revenue Growth
N/A
★ 13.83
52 Week Low
$11.09
$23.01
52 Week High
$30.06
$47.40

Technical Indicators

Market Signals
Indicator
IMNM
ELMD
Relative Strength Index (RSI) 31.21 34.64
Support Level $19.39 $27.14
Resistance Level $23.25 $29.57
Average True Range (ATR) 1.19 0.92
MACD -0.42 0.59
Stochastic Oscillator 1.42 77.17

Price Performance

Historical Comparison
IMNM
ELMD

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About ELMD Electromed Inc.

Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.

Share on Social Networks: